BioMérieux: Invest Securities raises target price

(CercleFinance.com) - While raising its target price from E130 to E133, Invest Securities reiterates its 'buy' rating on bioMérieux, a stock that it feels is insufficiently valued relative to its peers, given its market positioning and risk profile.


On Friday, the group announced 2024 results above expectations and exceeding targets. For 2025, targets are in line with the GO-28 plan and broadly in line with our expectations, the analyst says.

Particularly satisfied with the momentum of the four growth pillars, which are evolving at the top end of the GO-28 plan targets, the analyst believes that these levers are establishing bioMérieux as a true growth champion in the IVD market.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.